Historical position

J.P. Morgan Asset Management’s Biogen Inc (BIIB) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

JPMorgan Chase & Co. (consolidated SEC filer)Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2015Earliest verified positive filing snapshot
Latest statusHistorical positionBased on the latest supported relationship state
Peak shares5.85MHighest verified quarter-end share count
Quarters reported19Verified quarters with shares above zero
What happened?

JPMorgan Chase & Co. (consolidated SEC filer) first reported Biogen Inc in Q1 2015. The reported position was increased and reduced across later filings. Verified positive position history runs through Q4 2024. The current relationship status cannot be determined reliably from supported data.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2024
Sold 60.1% of the position−3.16M shares · 2.10M shares remained
Filing context

Quarter-end price $152.92

Q3 2024
Bought 11.6% more+544.97K shares · 5.26M shares reported after the change
Filing context

Quarter-end price $193.84

Q2 2024
Sold 0.2% of the position−7.79K shares · 4.71M shares remained
Filing context

Quarter-end price $231.82

Q1 2024
Sold 6.9% of the position−352.50K shares · 4.72M shares remained
Filing context

Quarter-end price $215.63

Q4 2023
Bought 1.7% more+87.01K shares · 5.07M shares reported after the change
Filing context

Quarter-end price $258.77

Q3 2023
Bought 11.5% more+514.56K shares · 4.99M shares reported after the change
Filing context

Quarter-end price $257.01

Portfolio importance

How important was Biogen Inc in JPMorgan Chase & Co. (consolidated SEC filer)’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.0%Q4 2024
Last reported rank#511Rank unavailable
Peak portfolio weight0.6%Q1 2015
Best historical rank#24Q1 2015
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$226.362026-09-24

Market context only; not an investor transaction price.

Latest filing quarter-end price$152.92Q4 2024

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-12
Open SEC filing ↗

The reported holdings and portfolio value cover JPMorgan Chase & Co.'s consolidated 13F filing, not J.P. Morgan Asset Management alone, a single fund, or the firm's total assets under management. The displayed holdings and history are bounded selections; weights use the full reported 13F value. Portfolio performance is not published, and position-level estimates remain withheld unless their evidence gates pass.